← Ginkgo Bioworks Holdings, Inc.
| Annual Trend | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $54.2m |
$76.7m
+41.48%
|
$313.8m
+309.40%
|
$477.7m
+52.21%
|
$251.5m
-47.36%
|
$227.0m
-9.71%
|
$170.2m
-25.06%
|
$132.4m
-22.18%
|
|
| Cost of revenue | $0 | $15.6m |
$129.7m
+730.76%
|
$204.2m
+57.46%
|
$54.0m
-73.55%
|
$44.5m
-17.51%
|
$47.0m
+5.44%
|
$42.3m
-9.91%
|
|
| Gross Profit | $54.2m |
$61.0m
+12.66%
|
$184.1m
+201.65%
|
$273.5m
+48.52%
|
$197.4m
-27.80%
|
$182.5m
-7.57%
|
$123.2m
-32.50%
|
$90.1m
-26.86%
|
|
| Research and development | $96.3m | $159.8m | $1.1b | $1.1b | $580.6m | $424.1m | $243.8m | $215.6m | |
| General and administrative | $29.5m | $38.3m | $863.0m | $1.4b | $385.0m | $246.2m | $183.3m | $177.2m | |
| Restructuring charges | — | — | — | $0 | $0 | $24.2m | $11.4m | — | |
| Total operating expenses | $125.8m | $213.7m | $2.1b | $2.7b | $1.1b | $786.8m | $485.4m | $435.1m | |
| Loss from operations | ($71.6m) |
($137.0m)
-91.38%
|
($1.8b)
-1234.38%
|
($2.2b)
-20.81%
|
($864.4m)
+60.87%
|
($559.8m)
+35.24%
|
($315.3m)
+43.68%
|
— | |
| Interest expense | ($2.4m) | ($2.4m) | ($2.4m) | ($106k) | ($93k) | ($94k) | $0 | $0 | |
| Interest income | $5.8m | $2.6m | $837k | $20.3m | $57.2m | $38.6m | $22.6m | $17.3m | |
| Loss on equity method investments | ($27.5m) | ($396k) | ($77.3m) | ($43.8m) | ($2.6m) | $0 | $0 | — | |
| Total other income (expense) | — | $12.2m | ($9.7m) | $87.6m | ($28.5m) | $12.2m | $1.7m | — | |
| Loss before income taxes | ($119.8m) | ($124.8m) | ($1.8b) | ($2.1b) | ($892.9m) | ($547.5m) | ($313.6m) | — | |
| Income tax benefit | $22k | $1.9m | ($1.5m) | ($15.0m) | ($71k) | ($479k) | ($837k) | — | |
| Net loss | ($119.9m) | ($126.7m) | ($1.8b) | ($2.1b) | ($892.9m) | ($547.0m) | ($312.8m) | — | |
| Basic (in dollars per share) | ($0.10) | ($0.10) | ($1.35) | ($1.25) | ($0.46) | ($10.54) | ($5.64) | — | |
| Diluted (in dollars per share) | ($0.10) | ($0.10) | ($1.39) | ($1.25) | ($0.46) | ($10.54) | ($5.64) | — | |
| Weighted average common shares outstanding, diluted (in shares) | 1.1b | 1.3b | 1.4b | 1.7b | 1.9b | 51.9m | 55.5m | — | |
| Impairment of lease assets | — | — | $0 | $0 | $96.2m | $0 | $0 | — | |
| Goodwill impairment | — | — | — | $0 | $0 | $47.9m | $0 | $0 | |
| Loss on investments | ($27.2m) | ($3.7m) | ($11.5m) | ($53.3m) | ($54.8m) | ($28.8m) | ($16.4m) | — | |
| Loss on deconsolidation of subsidiaries | — | $0 | $0 | $31.9m | ($42.5m) | ($7.0m) | $0 | — | |
| Change in fair value of warrant liabilities | $0 | $0 | $58.6m | $125.0m | $5.2m | $5.7m | $0 | — | |
| Other (expense) income, net | $1.6m | $7.8m | ($1.7m) | $7.6m | $9.1m | $3.9m | ($4.5m) | — | |
| Foreign currency translation adjustment | — | — | ($1.7m) | ($917k) | $4.1m | ($4.8m) | $3.5m | — | |
| Reclassification of foreign currency translation adjustment realized upon sale of foreign subsidiary | — | — | — | $0 | $0 | $1.5m | $0 | — | |
| Unrealized gain on available-for-sale securities | — | — | — | — | $0 | $0 | ($126k) | — | |
| Comprehensive loss | ($119.9m) | ($126.7m) | ($1.8b) | ($2.1b) | ($888.8m) | ($550.3m) | ($309.1m) | — | |
| Total other comprehensive income (loss) | — | — | — | ($917k) | $4.1m | ($3.3m) | $3.7m | — |
Values abbreviated: b = billions, m = millions, k = thousands. Per share data in USD.